4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Hemochromatosis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 22 ongoing clinical trials involving Hemochromatosis
Of the 22 trials,16 trials are in Phase II
Furthermore, 2 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Hemochromatosis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Hemochromatosis, a genetic disorder. The largest number of ongoing clinical trials for Hemochromatosis is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Hemochromatosis-related drug trials.

Hemochromatosis related clinical trial sponsor

Protagonist Therapeutics Inc, Jichi Medical University, Kagoshima City Hospital, Novartis AG, Vifor Pharma Ltd, National Center for Child Health and Development, Kanazawa University Hospital, AND University Health Network are among other notable clinical trial sponsors involved in Hemochromatosis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Hemochromatosis

Deferoxamine mesylate (Desferal), Deferasirox, and Deferasirox ODT (Deferasirox) are among the key marketed drugs involving Hemochromatosis.

Deferoxamine mesylate (Desferal) is an iron-chelating agent. It functions via Iron Chelator mechanism of action. It is formulated as injection for intravenous, intramuscular or subcutaneous route of administration. Deferoxamine mesylate is marketed for the treatment of Hemochromatosis and several other indications including Thalassemia, Acquired (Autoimmune) Hemolytic Anemia, and Iron Poisoning. Deferoxamine mesylate was first approved in 1963 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Novartis AG and its subsidiaries.

Deferasirox is an iron chelating agent. It functions via Iron Chelator mechanism of action. It is formulated as tablets for oral route of administration. Deferasirox is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. Deferasirox was first approved in 2019 and is marketed in the US by Piramal Healthcare UK Ltd.